Claims for Patent: 4,695,590

Summary for Patent: 4,695,590

Title:	Method for retarding aging
Abstract:	Methods and compositions are provided for retarding aging, i.e., inhibiting damage to human cells caused by toxic byproducts of oxygen metabolism. The anti-aging active ingredient is a compound or mixture of compounds represented by the following structural formula: ##STR1## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represent hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Inventor(s):	Lippman; Richard D. (Scottsdale, AZ)
Assignee:	California Health Technologies (Los Angeles, CA)
Application Number:	06/859,464
Patent Claims:	1. A method for retarding aging in humans by administering to a human a daily dosage of from about 0.5 mg per kilogram of body weight to less than about 2 mg per kilogram of body weight of a pharmaceutically acceptable composition comprising a compound or a mixture of compounds represented by the following structural formula: ##STR6## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof. 2. The method according to claim 1 wherein the compound is nordihydroguairetic acid. 3. The method according to claim 1 wherein the compound is bis(p-hydroxyphenyl)methane. 4. The method according to claim 1 wherein the composition is administered orally. 5. The method according to claim 1 wherein the composition is administered by a means selected from the group consisting of intravenously, subcutaneously, intramuscularly and intracutaneously. 6. A pharmaceutical composition in solid dosage form for retarding aging in humans consisting essentially of a compound or mixture of compounds represented by the following structural formula as the active ingredient: ##STR7## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof, wherein from about 20 mg to 100 mg of said active ingredient is present in the composition. 7. A composition as is claimed in claim 6 wherein the compound is nordihydroguairetic acid. 8. A composition as is claimed in claim 6 wherein the compound is bis(p-hydroxyphenyl)methane. 9. A pharmaceutical composition for topical administration to the skin of a human consisting essentially of an effective amount of a compound or mixture of compounds represented by the following structural formula as the only active ingredient in a topical pharmaceutically acceptable carrier: ##STR8## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof. 10. A composition as is claimed in claim 9 wherein the compound is nordihydroguairetic acid. 11. A composition as is claimed in claim 9 wherein the compound is bis(p-hydroxyphenyl)methane. 12. A composition as is claimed in claim 10 wherein the composition contains from about 0.5% to about 20% by weight of nordihydroguairetic acid compared to the total weight of the composition. 13. A pharmaceutical composition for topical administration to the skin of a human consisting essentially of a compound or mixture of compounds represented by the following structural formula as the acitve ingredient in a topical pharmaceutically acceptable carrier, wherein the composition contains from about 0.5% to about 20% by weight of the active ingredient compared to the total weight of the composition: ##STR9## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 andR3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof. 14. A composition as is claimed in claim 13 wherein the compound is nordihydroguairetic acid. 15. A composition as is claimed in claim 13 wherein the compound is bis(p-hydroxyphenyl)methane. 16. A composition as is claimed in claim 14 wherein the composition contains from about 0.5% to about 20% by weight of nordihydroguairetic acid compared to the total weight of the composition.